- Home
- GHM vs SEPN Comparison
GHM vs SEPN Comparison
Compare GHM & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHM
- SEPN
- Stock Information
- Founded
- GHM 1936
- SEPN 2022
- Country
- GHM United States
- SEPN United States
- Employees
- GHM N/A
- SEPN N/A
- Industry
- GHM Industrial Machinery/Components
- SEPN
- Sector
- GHM Industrials
- SEPN
- Exchange
- GHM Nasdaq
- SEPN NYSE
- Market Cap
- GHM 409.5M
- SEPN 453.2M
- IPO Year
- GHM N/A
- SEPN 2024
- Fundamental
- Price
- GHM $50.90
- SEPN $10.49
- Analyst Decision
- GHM Buy
- SEPN Strong Buy
- Analyst Count
- GHM 2
- SEPN 5
- Target Price
- GHM $45.00
- SEPN $26.75
- AVG Volume (30 Days)
- GHM 118.0K
- SEPN 541.8K
- Earning Date
- GHM 06-09-2025
- SEPN 08-15-2025
- Dividend Yield
- GHM N/A
- SEPN N/A
- EPS Growth
- GHM 164.29
- SEPN N/A
- EPS
- GHM 1.11
- SEPN N/A
- Revenue
- GHM $209,896,000.00
- SEPN $977,000.00
- Revenue This Year
- GHM $10.67
- SEPN N/A
- Revenue Next Year
- GHM $9.35
- SEPN $526.96
- P/E Ratio
- GHM $45.56
- SEPN N/A
- Revenue Growth
- GHM 13.13
- SEPN 108.76
- 52 Week Low
- GHM $24.78
- SEPN $4.17
- 52 Week High
- GHM $52.00
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- GHM 76.38
- SEPN N/A
- Support Level
- GHM $45.00
- SEPN N/A
- Resistance Level
- GHM $51.28
- SEPN N/A
- Average True Range (ATR)
- GHM 1.75
- SEPN 0.00
- MACD
- GHM 0.17
- SEPN 0.00
- Stochastic Oscillator
- GHM 94.74
- SEPN 0.00
About GHM Graham Corporation
Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.